ReportGem ReportGem

U.S. COMPANY FILING

NOVO NORDISK A S — Form 6-K filed 2025-09-10

Filed: 2025-09-10Company: NOVO NORDISK A STicker: NVOExchange: NYSEForm: 6-KReport period: 2025-09-10SEC accession: 0001171843-25-005809Event: earningsMateriality: 85

Filing text preview

On September 10, 2025, Novo Nordisk announced a company-wide transformation to simplify operations and reallocate resources to diabetes and obesity. It plans to cut about 9,000 roles globally (5,000 in Denmark), aiming for DKK 8 billion in annualized savings by end-2026. One-off restructuring costs of DKK 8 billion will lower 2025 operating profit growth outlook to 4-10% at CER from 10-16%. The move responds to a more competitive, consumer-driven obesity market.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2025-09-10Super Micro Says Top Management Didn't Know of Diversion Scheme2026-08-20Deoleo Shareholders Review Strategic Alternatives for Olive-Oil Business2026-08-20SSE Issues Regulatory Work Letter to Nanmo Bio2026-08-20Autohome Inc. files Form 6-K2026-08-20Sadot Group Inc. Files 8-K: Material Definitive Agreement and Unregistered Sales of Equity Securities2026-08-20WANG ON GROUP: Major transaction regarding disposal of target company and notice of extraordinary general meeting2026-08-206-K2026-08-04 · 6-K